A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease

Autor: Astrid G. S. van Halteren, Jessica S. Suwandi, Sander Tuit, Jelske Borst, Sandra Laban, Roula Tsonaka, Ada Struijk, Anna-Sophia Wiekmeijer, Melissa van Pel, Bart O. Roep, Jaap Jan Zwaginga, Arjan C. Lankester, Koen Schepers, Maarten J. D. van Tol, Willem E. Fibbe

Publikováno v: Blood. 141(11):1277-1292

Acute graft-versus-host disease (aGVHD) is an immune cell‒driven, potentially lethal complication of allogeneic hematopoietic stem cell transplantation affecting diverse organs, including the skin, liver, and gastrointestinal (GI) tract. We applied

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4806f577f9ab625e12cf2e9aa317027
https://doi.org/10.1182/blood.2022015734

Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis

Autor: Xin Lei, Paul Geraeds Kemps, Tom de Wit, Jelske Borst, Yanling Xiao, Jannie Borst, Rhianne Voogd, Joanna Grabowska, Eline C. Steenwijk, Astrid G. S. van Halteren, Cor van den Bos, Jennifer Picarsic

Publikováno v: Blood, 136(19), 2188-2199. American Society of Hematology
Blood, 136(19), 2188-2199. AMER SOC HEMATOLOGY
Xiao, Y, van Halteren, A G S, Lei, X, Borst, J, Steenwijk, E, de Wit, T, Grabowska, J, Voogd, R, Kemps, P, Picarsic, J, van den Bos, C & Borst, J 2020, ' Bone marrow-derived myeloid progenitors as driver mutation carriers in high-and low-risk Langerhans cell histiocytosis ', Blood, vol. 136, no. 19, pp. 2188-2199 . https://doi.org/10.1182/blood.2020005209

Langerhans cell histiocytosis (LCH) is a myeloid neoplasia, driven by sporadic activating mutations in the MAPK pathway. The misguided myeloid dendritic cell (DC) model proposes that high-risk, multisystem, risk-organ–positive (MS-RO+) LCH results

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::831f00941aad7d8d8051b4c17ac0aba1
https://pubmed.ncbi.nlm.nih.gov/32750121

Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis

Autor: Paul G. Kemps, Timo C. Zondag, Eline C. Steenwijk, Quirine Andriessen, Jelske Borst, Sandra Vloemans, Dave L. Roelen, Lenard M. Voortman, Robert M. Verdijk, Carel J. M. van Noesel, Arjen H. G. Cleven, Cynthia Hawkins, Veronica Lang, Arnoud H. de Ru, George M. C. Janssen, Geert W. Haasnoot, Kees L. M. C. Franken, Ronald van Eijk, Nienke Solleveld-Westerink, Tom van Wezel, R. Maarten Egeler, Auke Beishuizen, Jan A. M. van Laar, Oussama Abla, Cor van den Bos, Peter A. van Veelen, Astrid G. S. van Halteren

Publikováno v: Frontiers in Immunology, 10:3045. Frontiers Media S.A.
Frontiers in immunology, 10. Frontiers Media S.A.
Frontiers in Immunology, 10. FRONTIERS MEDIA SA
Frontiers in Immunology, Vol 10 (2020)

Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed with various immune cells, including T cells. In 50-60% of LCH-patients, t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16ee33415361be0bcb63b76235642c4
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85078689874&origin=inward